{
 "as_of": "2026-11-08",
 "cmr": "us-cm-kg/NASDAQ/VKTX",
 "fence": "The page is the record's research on the issuer — no analyst, no rating, no view.",
 "markdown": "The page is the record's research on the issuer — no analyst, no rating, no view.\n\n# Viking Therapeutics, Inc. (NASDAQ: VKTX) — research page\n\nAs of 2026-11-08 · us-cm-kg · record version 1\n\n## Identity and listing\n\nThe issuer is Viking Therapeutics, Inc., listed on NASDAQ under ticker VKTX, with ISIN US92686J1060 and LEI 529900IVC72YPFA25M37. Its security type is Corporate, its segment is not on the record, its sector is 2834 Pharmaceutical Preparations, and its jurisdiction is United States, Delaware. Its listing status is listed, not halted.\n\n## The disclosure read\n\nThe record holds 49 filings in the twelve months to 2026-11-08, across 22 filing days. The median gap between filing days is 8 days. The latest filing is dated 2026-11-05, 3 days before the record date, and is of type regulatory filing. The NASDAQ exchange median is 52 filings, a cadence gap of 6.0 days, and a latency of 5.0 days. The 2834 Pharmaceutical Preparations sector median is 63.0 filings, a cadence gap of 6.0 days, and a latency of 4.0 days.\n\n## Auditor\n\nThe auditor is not on the record, because the latest annual report cover carries no dei:AuditorName tag. The auditor's location is not on the record. The record holds no auditor changes.\n\n## Events and halts\n\nThe record holds no listing, delisting or name change lines. The domicile change is not on the record, because EDGAR states no dated change of state of incorporation on a filing line. The segment move is not on the record, because the exchanges' tier transfers are not EDGAR filings. The halt flag is listed, not halted.\n\n## Orderability\n\nThe outcome is not determinable, because the chapter's orderability section carries no client categories and so the outcome cannot name its client category. The rule version is acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1, and the chapter is as of 2026-11-04.\n\n## Coverage\n\nThe issuer's own investor-relations page names 21 research houses: B. Riley Securities, BTIG, Cantor Fitzgerald, Goldman Sachs & Co. LLC, H.C. Wainwright & Co., Jefferies, J.P. Morgan, Lake Street Capital Markets, LLC, Leerink Partners, Maxim Group, Morgan Stanley, Oppenheimer, Raymond James, Stifel, Truist Securities, UBS Securities LLC, William Blair, Wolfe Research, Canaccord Genuity LLC, Laidlaw & Company, and Piper Sandler & Co.\n\n## Open research\n\nNo openly published research notes were found for the issuer.\n\n## Licensed\n\nLicensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.\n\n## As-of depth\n\nThe sealed years that hold the issuer are 2021, 2022, 2023, 2024, 2025 and 2026. The market's earliest sealed date is 2021-01-04. The live record began on 2026-09-12.\n\n## Sources\n\n9 source pages are named on this page; every value above carries its own source page and read date in the numbers.\n\n- https://www.sec.gov/files/company_tickers_exchange.json (identity.exchange)\n- https://mapping.gleif.org/api/v2/isin-lei/latest (identity.isin)\n- https://data.sec.gov/submissions/CIK0001607678.json (identity.jurisdiction)\n- https://mapping.gleif.org/api/v2/isin-lei/latest/download (identity.lei)\n- https://mcp.us-cm-kg.ai/events/NASDAQ/VKTX (the disclosure lines)\n- https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts (the halt flag)\n- https://mcp.us-cm-kg.ai/book/aio.json (the orderability chapter)\n- https://ir.vikingtherapeutics.com/analyst-coverage (coverage)\n- https://mcp.us-cm-kg.ai/record/NASDAQ/VKTX (the record)\n",
 "market": "US",
 "node": "us-cm-kg",
 "numbers": {
  "as_of_depth": {
   "issuer_years_sealed": [
    "2021",
    "2022",
    "2023",
    "2024",
    "2025",
    "2026"
   ],
   "live_record_began": "2026-09-12",
   "node_history_from": "2021-01-04",
   "node_years_sealed": [
    "2021",
    "2022",
    "2023",
    "2024",
    "2025",
    "2026"
   ],
   "record_version": 1,
   "sealed": true
  },
  "auditor": {
   "auditor": {
    "market": "US",
    "reason": "no dei:AuditorName tag on the latest annual report cover (foreign private issuers and older filings carry none)",
    "state": "not_on_record"
   },
   "auditor_firm_id": {
    "market": "US",
    "state": "not_on_record"
   },
   "auditor_location": {
    "market": "US",
    "state": "not_on_record"
   },
   "changes": []
  },
  "cmr": "us-cm-kg/NASDAQ/VKTX",
  "coverage": {
   "count": 21,
   "houses": [
    {
     "analyst": "Mayank Mamtani",
     "house": "B. Riley Securities",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.vikingtherapeutics.com/analyst-coverage",
     "state": "sourced"
    },
    {
     "analyst": "Jeet Mukherjee, Ph.D.",
     "house": "BTIG",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.vikingtherapeutics.com/analyst-coverage",
     "state": "sourced"
    },
    {
     "analyst": "Steve Seedhouse, Ph.D.",
     "house": "Cantor Fitzgerald",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.vikingtherapeutics.com/analyst-coverage",
     "state": "sourced"
    },
    {
     "analyst": "Richard Law, Ph.D.",
     "house": "Goldman Sachs & Co. LLC",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.vikingtherapeutics.com/analyst-coverage",
     "state": "sourced"
    },
    {
     "analyst": "Joseph Pantginis, Ph.D.",
     "house": "H.C. Wainwright & Co.",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.vikingtherapeutics.com/analyst-coverage",
     "state": "sourced"
    },
    {
     "analyst": "Roger Song, M.D., CFA",
     "house": "Jefferies",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.vikingtherapeutics.com/analyst-coverage",
     "state": "sourced"
    },
    {
     "analyst": "Hardik Parikh, CFA",
     "house": "J.P. Morgan",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.vikingtherapeutics.com/analyst-coverage",
     "state": "sourced"
    },
    {
     "analyst": "Daniel Brims, Ph.D.",
     "house": "Lake Street Capital Markets, LLC",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.vikingtherapeutics.com/analyst-coverage",
     "state": "sourced"
    },
    {
     "analyst": "Thomas J. Smith",
     "house": "Leerink Partners",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.vikingtherapeutics.com/analyst-coverage",
     "state": "sourced"
    },
    {
     "analyst": "Naz Rahman, CFA",
     "house": "Maxim Group",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.vikingtherapeutics.com/analyst-coverage",
     "state": "sourced"
    },
    {
     "analyst": "Michael E. Ulz",
     "house": "Morgan Stanley",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.vikingtherapeutics.com/analyst-coverage",
     "state": "sourced"
    },
    {
     "analyst": "Jay Olson, CFA",
     "house": "Oppenheimer",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.vikingtherapeutics.com/analyst-coverage",
     "state": "sourced"
    },
    {
     "analyst": "Ryan Deschner, Ph.D.",
     "house": "Raymond James",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.vikingtherapeutics.com/analyst-coverage",
     "state": "sourced"
    },
    {
     "analyst": "Annabel Samimy",
     "house": "Stifel",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.vikingtherapeutics.com/analyst-coverage",
     "state": "sourced"
    },
    {
     "analyst": "Gregory J. Renza, M.D.",
     "house": "Truist Securities",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.vikingtherapeutics.com/analyst-coverage",
     "state": "sourced"
    },
    {
     "analyst": "Joon Lee M.D., Ph.D.",
     "house": "UBS Securities LLC",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.vikingtherapeutics.com/analyst-coverage",
     "state": "sourced"
    },
    {
     "analyst": "Andy Hsieh, Ph.D.",
     "house": "William Blair",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.vikingtherapeutics.com/analyst-coverage",
     "state": "sourced"
    },
    {
     "analyst": "Alexandria Hammond, Ph.D.",
     "house": "Wolfe Research",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.vikingtherapeutics.com/analyst-coverage",
     "state": "sourced"
    },
    {
     "analyst": "Edward Nash",
     "house": "Canaccord Genuity LLC",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.vikingtherapeutics.com/analyst-coverage",
     "state": "sourced"
    },
    {
     "analyst": "Yale Jen, Ph.D.",
     "house": "Laidlaw & Company",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.vikingtherapeutics.com/analyst-coverage",
     "state": "sourced"
    },
    {
     "analyst": "Biren Amin",
     "house": "Piper Sandler & Co.",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.vikingtherapeutics.com/analyst-coverage",
     "state": "sourced"
    }
   ],
   "pages_checked": [
    {
     "page": "https://ir.vikingtherapeutics.com/analyst-coverage",
     "result": "read: 21 of 39 named houses found on the page"
    }
   ],
   "read_by": "Perplexity sonar (search) · page read by this rail",
   "read_date": "2026-11-11",
   "since": "not stated on the page read",
   "state": "found"
  },
  "disclosure": {
   "against": {
    "exchange": {
     "issuers": 4359,
     "median_cadence_gap_days": 6,
     "median_filings": 52,
     "median_latency_days": 5,
     "name": "NASDAQ"
    },
    "sector": {
     "issuers": 526,
     "median_cadence_gap_days": 6,
     "median_filings": 63,
     "median_latency_days": 4,
     "name": "2834 Pharmaceutical Preparations"
    }
   },
   "by_type": {
    "agm_egm": 3,
    "corporate_news": 2,
    "directors_dealings": 18,
    "prospectus": 5,
    "regulatory_filing": 13,
    "results": 8
   },
   "cadence_median_gap_days": 8,
   "filing_days": 22,
   "filings": 49,
   "latency_days": 3,
   "latest": [
    {
     "category": "SCHEDULE 13G/A",
     "date": "2026-11-05",
     "source": "https://www.sec.gov/Archives/edgar/data/1607678/000031506626002856/xslSCHEDULE_13G_X02/primary_doc.xml",
     "title": "SCHEDULE 13G/A",
     "type": "regulatory_filing"
    },
    {
     "category": "10-Q",
     "date": "2026-10-29",
     "source": "https://www.sec.gov/Archives/edgar/data/1607678/000119312526436432/vktx-20260930.htm",
     "title": "10-Q — 10-Q",
     "type": "results"
    },
    {
     "category": "8-K",
     "date": "2026-10-28",
     "source": "https://www.sec.gov/Archives/edgar/data/1607678/000119312526436145/vktx-20261028.htm",
     "title": "8-K — 8-K (items 2.02,9.01)",
     "type": "results"
    },
    {
     "category": "8-K",
     "date": "2026-09-28",
     "source": "https://www.sec.gov/Archives/edgar/data/1607678/000119312526405580/vktx-20260923.htm",
     "title": "8-K — 8-K (items 1.01,2.03,9.01)",
     "type": "corporate_news"
    },
    {
     "category": "424B5",
     "date": "2026-09-25",
     "source": "https://www.sec.gov/Archives/edgar/data/1607678/000119312526401385/vktx-20260925.htm",
     "title": "424B5 — 424B5",
     "type": "prospectus"
    }
   ],
   "latest_filing_date": "2026-11-05",
   "read": "the node's event lines (list_events_since), as get_filings serves them",
   "source": "https://mcp.us-cm-kg.ai/events/NASDAQ/VKTX",
   "window": {
    "from": "2025-11-08",
    "to": "2026-11-08"
   }
  },
  "identity": {
   "exchange": {
    "read_by": "EDGAR company_tickers_exchange.json (SEC list of exchange-listed filers)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/files/company_tickers_exchange.json",
    "state": "sourced",
    "value": "NASDAQ"
   },
   "isin": {
    "read_by": "GLEIF ISIN-to-LEI mapping file (ISINs mapped to the LEI)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://mapping.gleif.org/api/v2/isin-lei/latest",
    "state": "sourced",
    "value": "US92686J1060"
   },
   "jurisdiction": {
    "read_by": "EDGAR submissions API (issuer header as filed) (stateOfIncorporation)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0001607678.json",
    "state": "sourced",
    "value": "United States — Delaware"
   },
   "lei": {
    "read_by": "GLEIF ISIN-to-LEI mapping file (daily), LEI by exact ISIN",
    "read_date": "2026-11-08",
    "read_date_basis": "the field",
    "source": "https://mapping.gleif.org/api/v2/isin-lei/latest/download (ISIN US92686J1060)",
    "state": "sourced",
    "value": "529900IVC72YPFA25M37"
   },
   "name": {
    "read_by": "EDGAR submissions API (issuer header as filed)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0001607678.json",
    "state": "sourced",
    "value": "Viking Therapeutics, Inc."
   },
   "sector": {
    "read_by": "EDGAR submissions API (issuer header as filed) (SIC code as assigned by the SEC)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0001607678.json",
    "state": "sourced",
    "value": "2834 Pharmaceutical Preparations"
   },
   "security_type": {
    "read_by": "EDGAR submissions API (issuer header as filed)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0001607678.json",
    "state": "sourced",
    "value": "Corporate"
   },
   "segment": {
    "market": "US",
    "state": "not_on_record"
   },
   "ticker": {
    "read_by": "EDGAR company_tickers_exchange.json (SEC list of exchange-listed filers)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/files/company_tickers_exchange.json",
    "state": "sourced",
    "value": "VKTX"
   },
   "website": {
    "market": "US",
    "state": "not_on_record"
   }
  },
  "licensed": {
   "columns": [
    "licensor",
    "entitlement",
    "title",
    "date",
    "source"
   ],
   "rows": [],
   "rule": "A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded."
  },
  "lifecycle": {
   "delisting": [],
   "domicile_change": {
    "market": "US",
    "reason": "EDGAR states no dated change of state of incorporation on a filing line",
    "state": "not_on_record"
   },
   "listing": [],
   "name_change": [],
   "segment_move": {
    "market": "US",
    "reason": "the exchanges' tier transfers are not EDGAR filings",
    "state": "not_on_record"
   }
  },
  "market": "US",
  "node": "us-cm-kg",
  "numbers_hash": "sha256:27059cb2de675ceb3a02f55a904591c0d8d12facfed1af6c374bee95a822ed98",
  "open_research": {
   "read_date": "2026-11-11",
   "rows": [],
   "state": "none_found"
  },
  "orderability": {
   "chapter_as_of": "2026-11-04",
   "client_categories": [],
   "determinable": false,
   "read": {
    "chapter": "https://mcp.us-cm-kg.ai/book/aio.json",
    "door": "https://mcp.us-cm-kg.ai/mcp",
    "tool": "get_orderability"
   },
   "reason": "the chapter's orderability section carries no client_categories: the outcome cannot name its client category",
   "rule_version": "acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1",
   "section": "us.aio.v8"
  },
  "record": {
   "as_of": "2026-11-08",
   "url": "https://mcp.us-cm-kg.ai/record/NASDAQ/VKTX",
   "version": 1
  },
  "schema": "research-numbers v0.1 (USR-01, 2026-11-11)",
  "status": {
   "read_date": "2026-11-08",
   "source": "https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts",
   "value": "listed, not halted"
  }
 },
 "numbers_hash": "sha256:27059cb2de675ceb3a02f55a904591c0d8d12facfed1af6c374bee95a822ed98",
 "path": "/us/NASDAQ/VKTX",
 "schema": "research-page v0.1 (USR-02, 2026-11-11)",
 "sections": [
  {
   "id": "identity",
   "text": "The issuer is Viking Therapeutics, Inc., listed on NASDAQ under ticker VKTX, with ISIN US92686J1060 and LEI 529900IVC72YPFA25M37. Its security type is Corporate, its segment is not on the record, its sector is 2834 Pharmaceutical Preparations, and its jurisdiction is United States, Delaware. Its listing status is listed, not halted.",
   "title": "Identity and listing"
  },
  {
   "id": "disclosure",
   "text": "The record holds 49 filings in the twelve months to 2026-11-08, across 22 filing days. The median gap between filing days is 8 days. The latest filing is dated 2026-11-05, 3 days before the record date, and is of type regulatory filing. The NASDAQ exchange median is 52 filings, a cadence gap of 6.0 days, and a latency of 5.0 days. The 2834 Pharmaceutical Preparations sector median is 63.0 filings, a cadence gap of 6.0 days, and a latency of 4.0 days.",
   "title": "The disclosure read"
  },
  {
   "id": "auditor",
   "text": "The auditor is not on the record, because the latest annual report cover carries no dei:AuditorName tag. The auditor's location is not on the record. The record holds no auditor changes.",
   "title": "Auditor"
  },
  {
   "id": "events",
   "text": "The record holds no listing, delisting or name change lines. The domicile change is not on the record, because EDGAR states no dated change of state of incorporation on a filing line. The segment move is not on the record, because the exchanges' tier transfers are not EDGAR filings. The halt flag is listed, not halted.",
   "title": "Events and halts"
  },
  {
   "id": "orderability",
   "text": "The outcome is not determinable, because the chapter's orderability section carries no client categories and so the outcome cannot name its client category. The rule version is acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1, and the chapter is as of 2026-11-04.",
   "title": "Orderability"
  },
  {
   "id": "coverage",
   "text": "The issuer's own investor-relations page names 21 research houses: B. Riley Securities, BTIG, Cantor Fitzgerald, Goldman Sachs & Co. LLC, H.C. Wainwright & Co., Jefferies, J.P. Morgan, Lake Street Capital Markets, LLC, Leerink Partners, Maxim Group, Morgan Stanley, Oppenheimer, Raymond James, Stifel, Truist Securities, UBS Securities LLC, William Blair, Wolfe Research, Canaccord Genuity LLC, Laidlaw & Company, and Piper Sandler & Co.",
   "title": "Coverage"
  },
  {
   "id": "open_research",
   "text": "No openly published research notes were found for the issuer.",
   "title": "Open research"
  },
  {
   "id": "licensed",
   "text": "Licensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.",
   "title": "Licensed"
  },
  {
   "id": "depth",
   "text": "The sealed years that hold the issuer are 2021, 2022, 2023, 2024, 2025 and 2026. The market's earliest sealed date is 2021-01-04. The live record began on 2026-09-12.",
   "title": "As-of depth"
  },
  {
   "id": "sources",
   "text": "9 source pages are named on this page; every value above carries its own source page and read date in the numbers.",
   "title": "Sources"
  }
 ],
 "sources": [
  {
   "for": "identity.exchange",
   "source": "https://www.sec.gov/files/company_tickers_exchange.json"
  },
  {
   "for": "identity.isin",
   "source": "https://mapping.gleif.org/api/v2/isin-lei/latest"
  },
  {
   "for": "identity.jurisdiction",
   "source": "https://data.sec.gov/submissions/CIK0001607678.json"
  },
  {
   "for": "identity.lei",
   "source": "https://mapping.gleif.org/api/v2/isin-lei/latest/download"
  },
  {
   "for": "the disclosure lines",
   "source": "https://mcp.us-cm-kg.ai/events/NASDAQ/VKTX"
  },
  {
   "for": "the halt flag",
   "source": "https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts"
  },
  {
   "for": "the orderability chapter",
   "source": "https://mcp.us-cm-kg.ai/book/aio.json"
  },
  {
   "for": "coverage",
   "source": "https://ir.vikingtherapeutics.com/analyst-coverage"
  },
  {
   "for": "the record",
   "source": "https://mcp.us-cm-kg.ai/record/NASDAQ/VKTX"
  }
 ],
 "title": "Viking Therapeutics, Inc. (VKTX) — research page",
 "writer": {
  "by": "Claude through the platform account, Haiku class; one pass; checked against the numbers",
  "engine": "claude-haiku-5-5"
 }
}